Tourlite Capital Management's Q3 2024 investor letter showcased the performance of Tourlite Fund, LP Founder Class, and highlighted Roivant Sciences Ltd. as a top pick. Roivant Sciences saw positive developments, including the launch of its new pipeline program, Mosliciguat.